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Hemorrhagic shock is a life-threatening condition
requiring a series of immediate interventions. Although
several details are still debated, there have been some
important achievements with great potential to influence
the care and outcomes of these patients.
The recognition of hemorrhagic shock should be based
on a combination of clinical, hemodynamic and bio-
chemical signs. The presence of low blood pressure
should not be a prerequisite of shock diagnosis, and
assessment of inadequate tissue perfusion by thorough
examination of cutaneous perfusion, urine output and
altered mental status together with laboratory signs of
anaerobic metabolism such as serum lactate and meta-
bolic acidosis should all be taken into account [1].
The main goals of the treatment of hemorrhagic shock
include the correction of the imbalance between oxygen
delivery (DO2) and consumption (VO2), maintaining
adequate perfusion pressure, and preventing or treating
coagulopathy (Fig. 1) [2].
The cornerstone of the initial management of the
bleeding patient is fluid resuscitation. Discussion of the
crystalloid-colloid debate goes well beyond the scope of
this article [3, 4]. However, based on a recent retrospec-
tive cohort study it has been proposed that low-volume
resuscitation with hypertonic saline may be preferable to
large-volume fluid loading before active bleeding has
been controlled in hemorrhagic shock [5, 6]. Therefore,
prospective studies are strongly warranted on this topic.
Tissue perfusion may also be improved by early
vasopressor administration. With careful blood pressure-
targeted titration of norepinephrine, life-threatening
hypotension and unnecessary fluid overload can be avoi-
ded. It is important to note, as stated in international
guidelines, that a low systolic blood pressure should be
tolerated until the cause of bleeding has been controlled
(in the absence of severe traumatic brain injuries) [1].
Tailoring fluid and vasopressor treatment requires
resuscitation end points. Pulse-contour-driven dynamic
variables such as stroke volume and pulse pressure vari-
ation may serve as useful measures to avoid both under-
and over-resuscitation. The parameters of tissue perfusion
and oxygen debt, such as lactate and base deficits, central
venous oxygen saturation (ScvO2) and a venous-to-arte-
rial CO2 gap, should also be put into context during
treatment [1, 7].
Apart from fluid resuscitation, the early administration
of blood products, such as red blood cells (RBCs), fresh
frozen plasma (FFP) and platelets, is often inevitable in
order to maintain DO2 and correct coagulation.
Regarding hemostasis management, the administration
of RBCs should be supplemented as soon as possible with
FFP to compensate for the deficit in coagulation factors.
There are two strategies for correcting hemostasis. So-
called ‘formula-driven’ resuscitation with a predeter-
mined RBC:FFP ratio serves as a fast and easy-to-use
approach to early correction of hemostasis. Recent ret-
rospective studies suggested an RBC:FFP ratio of
approximately 1:1 [8]. Although this concept is gradually
expanding from trauma to non-trauma bleeding
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management, the results of these studies are conflicting
and should be interpreted with caution because of the
potential for survival bias and substantial differences
between civilian and military trauma. In an international
prospective cohort, only combined high-dose FFP, cryo-
precipitate and platelet therapy with a high total
fibrinogen load appeared to produce a consistent
improvement in coagulation [9]. Undoubtedly the onset,
course and severity of coagulopathy differ depending on
the etiology. Therefore, it is likely that a given RBC:FFP
ratio does not fit all patients. Furthermore, the timing of
FFP administration may play a pivotal role in the out-
come; hence, it may be just as important, or even more so,
than the RBC:FFP ratio itself [10].
Unnecessary overuse of blood products can lead to
several complications [11]. However, individualized
‘goal-directed’ hemostatic resuscitation may help to
rationalize blood product utilization. Dynamic monitoring
of whole-blood coagulation provides several advantages
as compared to conventional plasma-based tests, such as
the prothrombin time, activated partial thromboplastin
time, international normalized ratio, fibrinogen and
platelet count. The latter tests are slow and mainly reflect
the initiation phase of thrombin generation. They cannot
be used to evaluate the primary hemostasis, clot strength
and fibrinolysis, which are also important pillars of
hemostasis and can often be impaired in severe bleeding.
Viscoelastic tests (such as the TEG or ROTEM), how-
ever, provide rapid and dynamic evaluation of clot
formation, strength and stability [12]. There is emerging
evidence that point-of-care tests based on ‘goal-directed’
coagulation management can modify the transfusion
strategy by providing better understanding of the under-
lying pathology and by the targeted use of not only FFP,
but also fibrinogen and prothrombin complex concen-
trates (PCC), hence reducing the need for blood products,
which enables the clinician to tailor hemostasis manage-
ment according to the patient’s needs [13]. Current
guidelines emphasize the importance of higher target
fibrinogen levels (1.5–2.0 g/l) and platelets of [50 g/l in
general, or [100 g/l in brain injury [14].
Regarding the adjunctive treatment of hemostasis,
there is strong evidence that tranexamic acid reduces
mortality; therefore, its early routine administration dur-
ing hemostatic resuscitation is recommended by
international guidelines [14–16]. Recombinant factor VII
can be considered only if major bleeding persists after all
efforts to support the fundamental pillars of hemostasis
have failed. Although we have satisfactory evidence that
the effects of vitamin K-dependent anticoagulants should
be reversed by PCC, in bleeding patients taking new
direct oral anticoagulants, its benefit remains controver-
sial [17]. Nevertheless, in the clinical routine there is no
other alternative to PCC at present, and hemodialysis can
be considered in patients taking dabigatran.
Considering the later phase of hemorrhagic shock
management, in addition to restrictive transfusion proto-
cols with a post-transfusion target of hemoglobin levels of
70–100 g/l, ‘physiological triggers’ such as the ScvO2
values have also been suggested to aid an individualized
approach by tailoring transfusion according to the
patient’s actual needs instead of a ‘numbers-driven’ pro-
tocolized care.
Finally, coordinated teamwork (including several dif-
ferent specialties) is essential in the management of
patients requiring massive transfusions. Implementation
of hospital-specific ‘massive transfusion protocols’ may
promote cooperation and accelerate the process, hence
improving outcomes in patients with severe bleeding [18].
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Fig. 1 Cornerstones of pathophysiology-based interventions
(a) and coagulation management (b) in hemorrhagic shock.
a VO2 Oxygen consumption; DO2 oxygen delivery; RBC red blood
cell; NE norepinephrine; IABP invasive arterial blood pressure;
PPV pulse pressure variation; SVV stroke volume variation; ScvO2
central venous oxygen saturation; dCO2 venous-to-arterial CO2
gap; FFP fresh frozen plasma. b Cai ionized calcium; Hb
hemoglobin; PCC prothrombin complex concentrate; FFP fresh
frozen plasma; INR international normalized ratio; TBI traumatic
brain injury; TXA tranexamic acid; FC fibrinogen concentrate;
rFVIIa recombinant activated factor VII; FXIII factor XIII
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In summary, this paradigm shift in the management of
hemorrhagic shock over the last decade provides several
alternatives for improving outcomes in hemorrhagic
shock patients; therefore, our current practice should be
reviewed and changes implemented if needed.
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